<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Linaclotide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Linaclotide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Linaclotide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="86369" href="/d/html/86369.html" rel="external">see "Linaclotide: Drug information"</a> and <a class="drug drug_patient" data-topicid="89332" href="/d/html/89332.html" rel="external">see "Linaclotide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F14944683"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of serious dehydration in pediatric patients younger than 2 years:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Linaclotide is contraindicated in pediatric patients younger than 2 years; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F15804379"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Linzess</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871489"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Constella</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56526112"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Gastrointestinal Agent, Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Guanylate Cyclase-C (GC-C) Agonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F58307910"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a81d8cd9-c577-4810-a7df-edc5f7729645">Functional constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Functional constipation:</b> Children ≥6 years and Adolescents &lt;18 years: Oral: 72 mcg once daily.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F58307911"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥6 years and Adolescents &lt;18 years: Oral: No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F58307912"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥6 years and Adolescents &lt;18 years: Oral: No dosage adjustment necessary.</p></div>
<div class="block doa drugH1Div" id="F15838398"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="86369" href="/d/html/86369.html" rel="external">see "Linaclotide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f7d0405-0daa-4433-ac8b-56835ffe8655">Chronic idiopathic constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic idiopathic constipation (CIC):</b>
<b>Oral:</b> 145 mcg once daily; 72 mcg once daily may be used based on patient presentation or tolerability.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9895d84-f23d-4ab8-b478-fe854563cc86">Irritable bowel syndrome with constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome with constipation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients with persistent constipation despite osmotic laxative use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 290 mcg once daily; dose may be reduced to 145 mcg once daily if patient develops diarrhea (typically occurs within 2 weeks). Symptoms of abdominal pain and bowel function generally improve by day 7 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30791771','lexi-content-ref-22986440','lexi-content-ref-31428193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30791771','lexi-content-ref-22986440','lexi-content-ref-31428193'])">Ref</a></span>); some experts will allow up to an 8- to 12-week trial before considering alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wald.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee392cb0-53e9-4092-abcf-46fc1f9a8332">Opioid-induced constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid-induced constipation (alternative agent) (off-label use): Oral:</b> 145 to 290 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32310620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32310620'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990080"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed: No supplemental dose or dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed: No dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987328"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block arsc drugH1Div" id="F57971729"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Diarrhea</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea </b>is the most commonly reported adverse reaction with linaclotide, leading to dose reduction, treatment interruption, and/or discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33315591','lexi-content-ref-35738724','lexi-content-ref-22986440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33315591','lexi-content-ref-35738724','lexi-content-ref-22986440'])">Ref</a></span>). Diarrhea was a patient-reported outcome in published experiences (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24917937','lexi-content-ref-29091082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24917937','lexi-content-ref-29091082'])">Ref</a></span>) and was not explicitly defined, but most frequently described as mild to moderate in severity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30791771','lexi-content-ref-29091082','lexi-content-ref-31428193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30791771','lexi-content-ref-29091082','lexi-content-ref-31428193'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action (activation of receptors in the intestines causing the release of chloride, bicarbonate, and fluid, which decreases intraluminal transit time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22986437','lexi-content-ref-24917937','lexi-content-ref-24939497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22986437','lexi-content-ref-24917937','lexi-content-ref-24939497'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; typically occurs within the first 1 to 2 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24917937','lexi-content-ref-30791771','lexi-content-ref-22986440','lexi-content-ref-28083815','lexi-content-ref-29091082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24917937','lexi-content-ref-30791771','lexi-content-ref-22986440','lexi-content-ref-28083815','lexi-content-ref-29091082'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose; occurred more frequently at higher doses in dose-finding studies and in postmarketing published experiences (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33876403','lexi-content-ref-24917937','lexi-content-ref-20801122','lexi-content-ref-30791771','lexi-content-ref-28083815','lexi-content-ref-29091082','lexi-content-ref-32022721','lexi-content-ref-23644388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33876403','lexi-content-ref-24917937','lexi-content-ref-20801122','lexi-content-ref-30791771','lexi-content-ref-28083815','lexi-content-ref-29091082','lexi-content-ref-32022721','lexi-content-ref-23644388'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of laxatives; especially at treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30302125']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30302125'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ethnicity (Caucasian) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30791771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30791771'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (≥65 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30791771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30791771'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F15838319"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults with irritable bowel syndrome with constipation or chronic idiopathic constipation unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (children and adolescents: 4% [severe diarrhea: &lt;1%]; adults: 16% to 22% [severe diarrhea: 2%])<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 1</a>)</span><span class="table-link" style="display:none;">Diarrhea</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Linaclotide: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Linaclotide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Linaclotide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">72 mcg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Functional constipation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">164</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">164</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe: &lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe: 0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">72 mcg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Functional constipation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">164</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">164</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145 mcg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic idiopathic constipation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">411</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">401</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">72 mcg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic idiopathic constipation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">411</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">401</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145 mcg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic idiopathic constipation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">430</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">423</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">290 mcg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Irritable bowel syndrome with constipation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">807</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">798</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe: 2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">290 mcg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Irritable bowel syndrome with constipation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">807</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">798</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (2% to 3%), abdominal pain (7%), bowel urgency (&lt;2%), dyspepsia (&lt;2%), fecal incontinence (&lt;2%), flatulence (4% to 6%), gastroesophageal reflux disease (&lt;2%), nausea (children and adolescents: 1%), viral gastroenteritis (≤3%), vomiting (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis (3%), upper respiratory tract infection (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hematochezia, rectal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p></div>
<div class="block coi drugH1Div" id="F15838287"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric patients &lt;2 years of age; mechanical gastrointestinal obstruction (known or suspected).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to linaclotide or any component of the formulation; pediatric patients &lt;6 years of age.</p></div>
<div class="block foc drugH1Div" id="F15804380"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Linzess: 72 mcg, 145 mcg, 290 mcg</p></div>
<div class="block geq drugH1Div" id="F15838282"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570451"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Linzess Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">72 mcg (per each): $21.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">145 mcg (per each): $21.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">290 mcg (per each): $21.64</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871490"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Constella: 72 mcg, 145 mcg, 290 mcg</p></div>
<div class="block admp drugH1Div" id="F58307913"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer at least 30 minutes before a meal; administer at the same time each day. Swallow capsule whole; do not break, crush, or chew capsules or capsule contents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>For patients with swallowing difficulties:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Administration in applesauce: Oral: Open capsule and sprinkle entire contents (beads) onto 5 mL (1 teaspoonful) of room temperature applesauce. Swallow entire contents immediately; do not chew the beads. Do not store mixture for future use. Mixing beads from capsules in other soft foods has not been tested.</p>
<p style="text-indent:-2em;margin-left:6em;">Administration in water: Oral: Open capsule and sprinkle entire contents (beads) into a cup with ~30 mL of room temperature bottled water. Gently swirl for at least 20 seconds and then swallow mixture immediately; add another 30 mL of water to any remaining beads in cup, swirl for at least 20 seconds, and swallow immediately. Do not store the water-bead mixture for future use. Mixing beads from capsules in other liquids has not been tested. <b>Note:</b> The drug is coated on surface of beads and will dissolve off the beads in water; beads will remain visible and will not dissolve; therefore, it is not necessary to consume all the beads to deliver complete dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>For administration via NG or gastric feeding tube</i>: Open capsule and empty entire contents (beads) into a clean container with 30 mL of room temperature bottled water. Gently swirl for at least 20 seconds; draw up bead and water mixture with catheter syringe and apply rapid and steady pressure (10 mL per 10 seconds) to dispense the bead-water mixture into the tube; add another 30 mL of water to any remaining beads and repeat process. Flush NG/gastric tube with at least 10 mL of water after administration. <b>Note:</b> Not necessary to flush all the beads through tube to deliver complete dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose</i>: If a dose is missed, skip the missed dose and administer next dose at regular time; do not double doses.</p></div>
<div class="block adm drugH1Div" id="F15838425"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral: </b>Administer at least 30 minutes before a meal on an empty stomach; loose stools and greater stool frequency may occur after administration with a high-fat breakfast. Swallow capsule whole; do not break, crush, or chew capsules or capsule contents.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients with swallowing difficulties, capsules may be opened and administered orally either in applesauce or with water or administered with water via a nasogastric or gastric feeding tube. Mixing beads from capsules in other soft foods or in other liquids has not been tested.</p>
<p style="text-indent:-2em;margin-left:2em;">Administration in applesauce: Open capsule and sprinkle entire contents (beads) onto 1 teaspoonful (5 mL) of room temperature applesauce. Swallow entire contents immediately; do not chew the beads. Do not store mixture for future use.</p>
<p style="text-indent:-2em;margin-left:2em;">Administration in water: Open capsule and sprinkle entire contents (beads) into a cup with ~30 mL of room temperature bottled water. Gently swirl for at least 20 seconds and swallow immediately; add another 30 mL of water to any remaining beads in cup, swirl for at least 20 seconds, and swallow immediately. Do not store the water-bead mixture for future use. <b>Note:</b> The drug is coated on surface of beads and will dissolve off the beads in water; beads will remain visible and will not dissolve; therefore, it is not necessary to consume all the beads to deliver complete dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Administration via nasogastric or gastric feeding tube: Open capsule and empty entire contents (beads) into a clean container with 30 mL of room temperature bottled water. Gently swirl for at least 20 seconds; draw up bead and water mixture with catheter syringe and apply rapid and steady pressure (10 mL per 10 seconds) to dispense the bead-water mixture into the tube; add another 30 mL of water to any remaining beads and repeat process. Flush nasogastric/gastric tube with at least 10 mL of water after administration. <b>Note:</b> Not necessary to flush all the beads through tube to deliver complete dose.</p></div>
<div class="block sts drugH1Div" id="F15838367"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F) in tightly closed, original container with included desiccant packet; excursions permitted between 15°C and 30°C (59°F and 86°F). Do not subdivide or repackage; protect from moisture.</p></div>
<div class="block meg drugH1Div" id="F15041819"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F202811s021lbl.pdf%23page%3D23&amp;token=R7NBd09Im9JRC%2FA9CBOHpAoAg8G%2Fg52IOpacLdTUbG2oj1PDYTVxV5iOG1Zja9rwe6C7eraIlfyvb%2B74AGYYzkwlmnDRY%2BSy1v882qOFTcK%2B0phjxscZKhCsi2QihQfw&amp;TOPIC_ID=141759" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202811s021lbl.pdf#page=23</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F58307909"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of functional constipation (FDA approved in ages 6 to 17 years); treatment of chronic idiopathic constipation (FDA approved in adults); treatment of irritable bowel syndrome with constipation (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F49161182"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">LinaCLOtide may be confused with linaGLIPtin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Linaclotide, when used in pediatric patients &lt;6 years of age, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of death from dehydration (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F15896867"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F15896865"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block dic drugH1Div" id="F15838370"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer at least 30 minutes before a meal on an empty stomach. Loose stools and greater stool frequency may occur after administration with a high-fat breakfast.</p></div>
<div class="block pri drugH1Div" id="F15838284"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Linaclotide and its metabolite are not measurable in plasma when used at recommended doses. Maternal use is not expected to result in fetal exposure; however, until information specific to use in pregnancy becomes available, agents other than linaclotide may be preferred (Moosavi 2021).</p></div>
<div class="block mopp drugH1Div" id="F58307914"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Stool output, diarrhea, signs/symptoms of dehydration (particularly severe: dizziness, hypotension, electrolyte abnormalities [potassium, sodium]).</p></div>
<div class="block pha drugH1Div" id="F15838368"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Linaclotide and its active metabolite bind and agonize guanylate cyclase-C on the luminal surface of intestinal epithelium. Intracellular and extracellular cyclic guanosine monophosphate (cGMP) concentrations are subsequently increased resulting in chloride and bicarbonate secretion into the intestinal lumen. Intestinal fluid increases and GI transit is accelerated. Increased extracellular cGMP may decrease visceral pain by reducing pain-sensing nerve activity.</p></div>
<div class="block phk drugH1Div" id="F15838372"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Minimal systemic availability; plasma concentrations are not measurable when used at recommended doses.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Minimal tissue distribution is expected given immeasurable plasma concentrations when used at recommended doses.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized within GI tract to active metabolite; parent drug and metabolite undergo proteolytic degradation within the intestinal lumen to smaller peptides and amino acids</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily feces (3% to 5%; as the active metabolite)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059510"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Linazic | Motrax | Motrax 72 | Motrax md</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Axulta | Constella</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">LInzess</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">LInzess</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">LInzess</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">LInzess</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Constella</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">LInzess</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Constella</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33876403">
<a name="33876403"></a>Baaleman DF, Gupta S, Benninga MA, et al. The use of linaclotide in children with functional constipation or irritable bowel syndrome: a retrospective chart review. <i>Paediatr Drugs</i>. 2021;23(3):307-314. doi:10.1007/s40272-021-00444-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/33876403/pubmed" id="33876403" target="_blank">33876403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32310620">
<a name="32310620"></a>Brenner DM, Argoff CE, Fox SM, et al. Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study. <i>Pain</i>. 2020;161(5):1027-1036. doi:10.1097/j.pain.0000000000001754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/32310620/pubmed" id="32310620" target="_blank">32310620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35738724">
<a name="35738724"></a>Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. <i>Gastroenterology</i>. 2022;163(1):118-136. doi:10.1053/j.gastro.2022.04.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/35738724/pubmed" id="35738724" target="_blank">35738724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22986437">
<a name="22986437"></a>Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. <i>Am J Gastroenterol</i>. 2012;107(11):1702-1712. doi:10.1038/ajg.2012.254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/22986437/pubmed" id="22986437" target="_blank">22986437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-constella.1">
<a name="constella.1"></a>Constella (linaclotide) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24917937">
<a name="24917937"></a>Corsetti M, Tack J. Linaclotide: a new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation. <i>United European Gastroenterol J</i>. 2013;1(1):7-20. doi:10.1177/2050640612474446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/24917937/pubmed" id="24917937" target="_blank">24917937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31396746">
<a name="31396746"></a>Davies A, Leach C, Caponero R, et al. MASCC recommendations on the management of constipation in patients with advanced cancer. <i>Support Care Cancer</i>. 2020;28(1):23-33. doi:10.1007/s00520-019-05016-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/31396746/pubmed" id="31396746" target="_blank">31396746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20801122">
<a name="20801122"></a>Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. <i>Gastroenterology</i>. 2010;139(6):1877-1886.e2. doi:10.1053/j.gastro.2010.08.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/20801122/pubmed" id="20801122" target="_blank">20801122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33315591">
<a name="33315591"></a>Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. <i>Am J Gastroenterol</i>. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/33315591/pubmed" id="33315591" target="_blank">33315591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Linzess.2">
<a name="Linzess.2"></a>Linzess (linaclotide) [prescribing information]. North Chicago, IL: AbbVie Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24939497">
<a name="24939497"></a>Love BL, Johnson A, Smith LS. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome. <i>Am J Health Syst Pharm</i>. 2014;71(13):1081-1091. doi:10.2146/ajhp130575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/24939497/pubmed" id="24939497" target="_blank">24939497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191. doi:10.5863/1551-6776-25.3.175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33481381">
<a name="33481381"></a>Moosavi S, Pimentel M, Wong MS, Rezaie A. Irritable bowel syndrome in pregnancy. <i>Am J Gastroenterol</i>. 2021;116(3):480-490. doi:10.14309/ajg.0000000000001124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/33481381/pubmed" id="33481381" target="_blank">33481381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28034973">
<a name="28034973"></a>Müller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. <i>Pain Med</i>. 2017;18(10):1837-1863. doi:10.1093/pm/pnw255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/28034973/pubmed" id="28034973" target="_blank">28034973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30791771">
<a name="30791771"></a>Nee JW, Johnston JM, Shea EP, et al. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled phase 3 analysis. <i>Expert Rev Gastroenterol Hepatol</i>. 2019;13(4):397-406. doi:10.1080/17474124.2019.1575203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/30791771/pubmed" id="30791771" target="_blank">30791771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Portenoy.1">
<a name="Portenoy.1"></a>Portenoy RK, Mehta Z, Ahmed E. Prevention and management of side effects in patients receiving opioids for chronic pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22986440">
<a name="22986440"></a>Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. <i>Am J Gastroenterol</i>. 2012;107(11):1714-1724. doi:10.1038/ajg.2012.255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/22986440/pubmed" id="22986440" target="_blank">22986440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28083815">
<a name="28083815"></a>Rey E, Mearin F, Alcedo J, et al. Optimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome: an expert consensus report. <i>Adv Ther</i>. 2017;34(3):587-598. doi:10.1007/s12325-016-0473-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/28083815/pubmed" id="28083815" target="_blank">28083815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29091082">
<a name="29091082"></a>Schoenfeld P, Lacy BE, Chey WD, et al. Low-dose linaclotide (72 μg) for chronic idiopathic constipation: a 12-week, randomized, double-blind, placebo-controlled trial. <i>Am J Gastroenterol</i>. 2018;113(1):105-114. doi:10.1038/ajg.2017.230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/29091082/pubmed" id="29091082" target="_blank">29091082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31428193">
<a name="31428193"></a>Serrano-Falcón B, Delgado-Aros S, Mearin F, et al. Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms. <i>Therap Adv Gastroenterol</i>. 2019;12:1756284819857358. doi:10.1177/1756284819857358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/31428193/pubmed" id="31428193" target="_blank">31428193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022721">
<a name="32022721"></a>Shah ED, Suresh S, Jou J, Chey WD, Stidham RW. Evaluating when and why patients discontinue chronic therapy for irritable bowel syndrome with constipation and chronic idiopathic constipation. <i>Am J Gastroenterol</i>. 2020;115(4):596-602. doi:10.14309/ajg.0000000000000530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/32022721/pubmed" id="32022721" target="_blank">32022721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23644388">
<a name="23644388"></a>Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2013;11(9):1084-109.e3. doi:10.1016/j.cgh.2013.04.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/23644388/pubmed" id="23644388" target="_blank">23644388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32462777">
<a name="32462777"></a>Vijayvargiya P, Camilleri M, Vijayvargiya P, Erwin P, Murad MH. Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation. <i>Aliment Pharmacol Ther</i>. 2020;52(1):37-53. doi:10.1111/apt.15791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/32462777/pubmed" id="32462777" target="_blank">32462777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wald.1">
<a name="Wald.1"></a>Wald A. Treatment of irritable bowel syndrome in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30302125">
<a name="30302125"></a>Yiannakou Y, Agrawal A, Allen PB, et al. UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. <i>Therap Adv Gastroenterol</i>. 2018;11:1756284818798791. doi:10.1177/1756284818798791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/linaclotide-pediatric-drug-information/abstract-text/30302125/pubmed" id="30302125" target="_blank">30302125</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141759 Version 12.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
